Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Albitar

Showing results (131-140 of 214) with videos related to

Pageof 22
Sort By:
Blood|November 2, 2002
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignanciesJorge Cortes, Maher Albitar, Deborah Thomas, et al.
Blood|May 3, 2002
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyMichael J Keating, Ian Flinn, Vinay Jain, et al.
Leukemia Research|May 15, 2002
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndromeChung Wu Lin, Taghi Manshouri, Iman Jilani, et al.
Blood|March 23, 2006
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemiaCharles Koller, B Nebiyou Bekele, Xian Zhou, et al.
Transfusion|June 28, 2017
Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemiaCelina Montemayor-Garcia, Rebecca Coward, Maher Albitar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignanciesDavid A Rizzieri, Eric Feldman, John F Dipersio, et al.
Cancers|February 26, 2025
Updates on the Biological Heterogeneity of Mantle Cell LymphomaAndrew Ip, Maciej Kabat, Lindsay Fogel, et al.
Cancer|March 17, 2004
Thalidomide for patients with recurrent lymphomaBarbara Pro, Anas Younes, Maher Albitar, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disordersApostolia M Tsimberidou, Dawn E Colburn, Mary Alma Welch, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Pageof 22

Showing results (131-140 of 214) with videos related to

Sort By:
Pageof 22
Blood|November 2, 2002
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignanciesJorge Cortes, Maher Albitar, Deborah Thomas, et al.
Blood|May 3, 2002
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyMichael J Keating, Ian Flinn, Vinay Jain, et al.
Leukemia Research|May 15, 2002
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndromeChung Wu Lin, Taghi Manshouri, Iman Jilani, et al.
Blood|March 23, 2006
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemiaCharles Koller, B Nebiyou Bekele, Xian Zhou, et al.
Transfusion|June 28, 2017
Acquired RhD mosaicism identifies fibrotic transformation of thrombopoietin receptor-mutated essential thrombocythemiaCelina Montemayor-Garcia, Rebecca Coward, Maher Albitar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignanciesDavid A Rizzieri, Eric Feldman, John F Dipersio, et al.
Cancers|February 26, 2025
Updates on the Biological Heterogeneity of Mantle Cell LymphomaAndrew Ip, Maciej Kabat, Lindsay Fogel, et al.
Cancer|March 17, 2004
Thalidomide for patients with recurrent lymphomaBarbara Pro, Anas Younes, Maher Albitar, et al.
Cancer Chemotherapy and Pharmacology|June 5, 2003
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disordersApostolia M Tsimberidou, Dawn E Colburn, Mary Alma Welch, et al.
Cancer|February 25, 2003
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndromeJorge Cortes, Hagop Kantarjian, Maher Albitar, et al.
Pageof 22